Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
Cancer Chemotherapy and Pharmacology|March 5, 2018
Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancerSuguru Yamada, Tsutomu Fujii, Yukihiro Yokoyama, et al.
Investigational New Drugs|May 12, 2023
Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitisTakafumi Yamamoto, Kazuyuki Mizuno, Takanori Ito, et al.
Journal of Gastroenterology|March 4, 2020
Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignanciesKazuyuki Mizuno, Takanori Ito, Masatoshi Ishigami, et al.
World Journal of Gastroenterology|December 10, 2021
Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survivalKentaro Yamada, Tsunaki Sawada, Masanao Nakamura, et al.
Nagoya Journal of Medical Science|June 27, 2019
Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II studyNao Takano, Suguru Yamada, Akihiro Hirakawa, et al.
Hepatology International|August 10, 2021
Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignanciesTakanori Ito, Masatoshi Ishigami, Takafumi Yamamoto, et al.
International Journal of Clinical Oncology|January 25, 2020
Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncologyYoichi Naito, Saori Mishima, Kiwamu Akagi, et al.
Nagoya Journal of Medical Science|March 20, 2024
Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancerKoki Nakanishi, Chie Tanaka, Mitsuro Kanda, et al.
Japanese Journal of Clinical Oncology|February 15, 2008
Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancerYoshiyuki Kakehi, Toshiyuki Kamoto, Taizou Shiraishi, et al.
International Journal of Clinical Oncology|May 22, 2023
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumorsYoichi Naito, Saori Mishima, Kiwamu Akagi, et al.
Pageof 14